The evaluation of therapeutic effects and adverse effects of Imatinib in Secondary Progressive Multiple Sclerosis
Phase 2
- Conditions
- Multiple Sclerosis.Multiple sclerosis (MS), also known as
- Registration Number
- IRCT201210231584N3
- Lead Sponsor
- Vice chancellor for research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
SPMS patients with relapse; EDSS between 3 and 5; age between 18 and 40
Exclusion criteria: History of other autoimmune disorder or chronic hematologic, renal, liver or infectious diseases; Pregnancy; lactation; History of HIV and Hepatitis; History of cancer especially breast tumor; History of recent herpes zoster infection; History of cytotoxic drugs consumption during recent three months; History of high dose corticosteroid during recent two months.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical signs and symptoms. Timepoint: every one month. Method of measurement: Number of relapses during six months, EDSS changes.;Adverse effect. Timepoint: every one month. Method of measurement: biochemical test, clinical examination.
- Secondary Outcome Measures
Name Time Method umber of new plaques in MRI. Timepoint: six months. Method of measurement: Brain MRI with and without Gad.